Novel CB1R allosteric agonist-positive modulator (ago-PAM), exhibiting augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55940)

Antagonist of central cholecystokinin receptors

Novel non-toxic and mammalian-specific LINE-1 inhibitor

Selective inhibitor of carbonic anhydrase IX (CAIX)

Selective inhibitor of carbonic anhydrase IX (CAIX)

Highly potent non-nucleoside inhibitor of HIV-1 reverse transcriptase

Novel Potent and Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Novel glucosylceramide synthase (GCS) inhibitor, rescuing lysosomal deficits, α-synuclein pathology and neuron toxicity

Novel highly-selective oral checkpoint kinase 1 (Chk1) inhibitor

Novel potent, selective and orally bioavailable Chk1 inhibitor

Novel Bruton's tyrosine kinase (BTK) inhibitor

Novel SMAC mimetic and IAP antagonist

Inhibitor of the Wnt/beta-catenin signaling pathway, suppressing cell proliferation and enhancing radiosensitivity in A549/Wnt2 cells.

Novel Phosphodiesterase 4D (PDE4D) Inhibitor

MAO inhibitor

Novel antifungal agent

Metabolite of ganstigmine, a novel acetylcholinesterase inhibitor

Natural covalent Cys151-dependent NRF2 activator

Natural non-covalent NRF2 activator, activating NRF2 in A KEAP1-dependent but Cys151-independent manner, conferring greater protection than a Cys151-dependent analog, geopyxin C

Novel potent and highly selective CDK5 inhibitor (IC 50 : 2.3 nM)

Endogenous dipeptide, activating N-methyl-D-aspartate receptors

Novel nonpeptidic inverse agonist of the Ghrelin Receptor (GHSR)